Northwest Biotherapeutics Inc (NWBO) USD0.001

Sell:$0.21Buy:$0.21$0.00 (1.87%)

Prices delayed by at least 15 minutes
Sell:$0.21
Buy:$0.21
Change:$0.00 (1.87%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.21
Buy:$0.21
Change:$0.00 (1.87%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Key people

Linda F. Powers
Chairperson of the Board, President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer
Leslie J. Goldman
Senior Vice President, General Counsel
Alton L. Boynton
Chief Scientific Officer, Corporate Secretary, Director
Marnix L. Bosch
Chief Technical Officer
J. Cofer Black
Independent Director
Navid Malik
Independent Director
Pat Sarma
Independent Director

Key facts

  • EPIC
    NWBO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US66737P6007
  • Market cap
    $297.62m
  • Employees
    25
  • Shares in issue
    1.39bn
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.